(ADMINISTRATIVE CORE) The Administrative Core provides essential support to the MD Anderson Cancer Center and Temple/Fox Chase Cancer Center Leukemia SPORE PIs and investigators to maximize success. It is co-directed by Drs. Hagop Kantarjian and Jean-Pierre Issa, who co-chair the Executive Committee and provide overall supervision of five Projects, two additional Cores, Developmental Research (DRP) and Career Enhancement (CEP) Programs, and scientific direction of the SPORE. The Core co-Directors rely on the extensive broad-based scientific, research, and SPORE experience of the Internal and External Advisory Boards in critical decision- making. Success of the complex interdisciplinary research in the SPORE depends on integration of diverse leukemia research approaches. The Core will overcome barriers to interdisciplinary collaboration and data sharing and will ensure a unified translational research effort. The SPORE is founded on planning, integration, and translational research efforts supported by this Core. Its leadership and staff will be responsible for monitoring/planning scientific activities; providing scientific direction; ensuring emphasis on translational research; ensuring interdisciplinary and inter-SPORE integration with major leukemia programs within/outside MD Anderson and other broad translational research activities; and providing optimal administrative and fiscal management. Specific responsibilities of the Administrative Core are: Oversee and monitor all SPORE activities; promote integration and communication among the SPORE-related clinical programs; monitor the scientific integrity of all research projects, and grant awards; assure compliance with institutional, governmental, and National Cancer Institute regulations; oversee the fiscal and budgetary activities of the SPORE; coordinate data control quality assurance issues in conjunction with the Internal Advisory Board and the Biostatistics, Data Management, and Bioinformatics Core (Core 3); coordinate activities associated with clinical trials, including design of protocols, approval by regulatory bodies, implementation, and eligibility screening and assignment of patients to different studies; provide oversight and support for Core 3 and the Pathology and Tissue Core (Core 2); coordinate and manage meetings of the SPORE Executive Committee, the Internal and External Advisory Boards, monthly investigator meetings, quarterly research meetings, lectures, and symposia; administer the DRP and the CEP; coordinate interdisciplinary and inter-SPORE interactions and exchanges/meetings with other Leukemia SPORE programs and investigators, and other organ-site SPORE programs; administer the activities of the Patient Advocates; comply with, and improve policies addressing recruitment and retention of women and minorities; organize seminars to bring to MD Anderson consultants and speakers with expertise in various clinical and laboratory aspects of leukemia research; maintain a Leukemia SPORE website focused on issues in leukemia translational research.

Public Health Relevance

(Administrative Core) The Administrative Core provides the support and infrastructure for research and financial oversight; clear and open communications among all SPORE investigators, patient advocates, and developmental awardees; and regulatory monitoring to optimize the successful outcome of the translational research in leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-17
Application #
9762853
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
17
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yan, Fangrong; Zhu, Huihong; Liu, Junlin et al. (2018) Design and inference for 3-stage bioequivalence testing with serial sampling data. Pharm Stat 17:458-476
Kelly, Andrew D; Madzo, Jozef; Madireddi, Priyanka et al. (2018) Demethylator phenotypes in acute myeloid leukemia. Leukemia 32:2178-2188
Levis, Mark J; Perl, Alexander E; Altman, Jessica K et al. (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2:825-831
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Masarova, Lucia; Verstovsek, Srdan; Hidalgo-Lopez, Juliana E et al. (2018) A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132:1664-1674
Good, Charly Ryan; Panjarian, Shoghag; Kelly, Andrew D et al. (2018) TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer. Cancer Res 78:4126-4137
Choi, Sangbum; Kang, Sangwook; Huang, Xuelin (2018) Smoothed quantile regression analysis of competing risks. Biom J 60:934-946
Boddu, Prajwal; Kantarjian, Hagop; Garcia-Manero, Guillermo et al. (2018) The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 59:790-802
Yang, Tian-Hui; St John, Lisa S; Garber, Haven R et al. (2018) Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. J Immunol 201:1389-1399
Rivera-Del Valle, Nilsa; Cheng, Tiewei; Irwin, Mary E et al. (2018) Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol 81:483-495

Showing the most recent 10 out of 487 publications